Pyramid Cardiovascular Biotechnology Co., Ltd. of Canada, headquartered in the beautiful and pleasant Vancouver, integrates health education, consulting, lectures, R&D, and production. Founded by cardiovascular expert and researcher Dr. Danny Lee, the company is a British Columbia, Canada-based biotechnology company focused on research into atherosclerosis, including the prevention and treatment of cardiovascular and cerebrovascular diseases, stroke, coronary heart disease, and myocardial infarction. It also develops and produces all-natural herbal health products.
The "Lingshu: Nine Needles and Twelve Origins" states: "Even if the disease persists, it can still be cured. Those who claim it is incurable have not mastered the art."
Dr. Danny Lee, a cardiovascular expert and researcher, inherited his family's medical tradition from a young age and subsequently pursued further professional training before becoming a practicing physician. During his 13 years of intensive study at the International Education College of Nanjing University of Chinese Medicine, he successfully completed a series of basic theoretical and clinical courses in both Traditional Chinese and Western medicine, including his bachelor's, master's, and doctoral degrees. During his training, he received personal guidance and support from renowned Chinese medical masters and numerous graduate advisors, earning him unanimous high praise and enthusiastic expectations. He has also participated in the editing and publication of over ten medical books, including "Tonic Chinese Medicine and Clinical Prescriptions" (for which he served as deputy editor). He has also published the paper "Benefits of Four-Season Health Preservation" (for which he served as independent author).
His 13-year medical training, like "ten years sharpening a sword," has enriched his understanding of clinical research and laid a solid foundation in both medical theory and clinical practice.
Dr. Danny Lee, in his over 20 years of medical practice, has diligently studied ancient teachings and learned from many others. He has been dedicated to exploring the mechanisms of cardiovascular and cerebrovascular diseases, conducting in-depth research on the pathogenesis of the "Four Highs" (hyperlipidemia, diabetes, and hyperuricemia), a globally prevalent disease, as well as the pathology of their complications. Breaking free from the shackles of outdated medical academic perspectives, he integrates Chinese and Western medicine, learning from the past without being bound by tradition, seeking the fundamentals, and boldly innovating.
Dr. Danny Lee's clinical research in cardiovascular and cerebrovascular diseases has achieved groundbreaking progress and is gaining increasing international recognition. He has been interviewed and participated in numerous seminars in related fields. For example, there were interviews with cardiovascular experts on Phoenix TV America in September 2021, December 2023, and February 2025.
In March 2025, in collaboration with China Pharmaceutical University, we conducted a project called (PCD#1) Pyramid Exploration 1, investigating the pharmacodynamic effects of traditional Chinese medicine on lowering blood pressure. This project primarily involved a group clinical trial of a formula in SHR hypertensive rats. The project was a complete success in June of the same year, and a patent application has been filed. In July of the same year, we conducted a pilot study on a type 1 diabetic mouse model. After one week of dosing, blood glucose levels in the treatment group decreased significantly compared to the model group, with a statistically significant difference (P<0.05). A further study will be conducted.